NasdaqCM:BLFSLife Sciences
Does BioLife’s 2026 Profitability Guidance and Media Strength Change The Bull Case For BLFS?
In February 2026, BioLife Solutions, Inc. reported fourth-quarter 2025 sales of US$24.76 million, full-year 2025 sales of US$96.21 million, a reduced full-year net loss of US$4.60 million, and issued 2026 revenue guidance of US$112.5 million to US$115.0 million alongside an expectation of GAAP net income for the year.
Management highlighted that growth was primarily driven by its biopreservation media franchise, now embedded in multiple approved cell and gene therapies, supported by a...